BLRX - CIK 0001498403
The table below shows BioLineRx Ltd.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | $950.00K | $19.68M | $1.11M | $0.00 | $0.00 | - |
| R&D | $8.09M | $9.15M | $12.52M | $17.63M | $19.47M | $18.17M |
| SG&A | $3.14M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $6.32M |
| $6.31M |
| $5.07M |
| $4.31M |
| $3.91M |
| Operating income | - | - | - | - | - | - |
| Income tax | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - |
| EPS (diluted) | - | - | - | - | - | - |